Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1957 1
1962 1
1963 1
1964 1
1965 1
1966 1
1967 3
1968 7
1969 2
1970 4
1971 1
1972 3
1973 6
1974 6
1975 9
1976 6
1977 4
1978 6
1979 7
1980 6
1981 3
1982 7
1983 9
1984 9
1985 6
1986 3
1987 12
1988 11
1989 8
1990 6
1991 1
1992 3
1993 4
1994 11
1995 6
1996 4
1997 5
1998 9
1999 10
2000 9
2001 9
2002 10
2003 10
2004 15
2005 17
2006 20
2007 11
2008 18
2009 21
2010 22
2011 25
2012 28
2013 38
2014 45
2015 43
2016 46
2017 41
2018 50
2019 44
2020 48
2021 56
2022 36
2023 46
2024 30

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

828 results

Results by year

Filters applied: . Clear all
Page 1
Propagative α-synuclein seeds as serum biomarkers for synucleinopathies.
Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno SI, Imamichi-Tatano Y, Kimura H, Kakuta S, Kondo A, Fukuhara T, Li Y, Funayama M, Saiki S, Taniguchi D, Tsunemi T, McIntyre D, Gérardy JJ, Mittelbronn M, Kruger R, Uchiyama Y, Nukina N, Hattori N. Okuzumi A, et al. Among authors: fukuhara t. Nat Med. 2023 Jun;29(6):1448-1455. doi: 10.1038/s41591-023-02358-9. Epub 2023 May 29. Nat Med. 2023. PMID: 37248302 Free PMC article.
Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants.
Tamura T, Ito J, Uriu K, Zahradnik J, Kida I, Anraku Y, Nasser H, Shofa M, Oda Y, Lytras S, Nao N, Itakura Y, Deguchi S, Suzuki R, Wang L, Begum MM, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Shimizu R, Tsuda M, Kosugi Y, Fujita S, Pan L, Sauter D, Yoshimatsu K, Suzuki S, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Yamamoto Y, Nagamoto T, Schreiber G, Maenaka K; Genotype to Phenotype Japan (G2P-Japan) Consortium; Hashiguchi T, Ikeda T, Fukuhara T, Saito A, Tanaka S, Matsuno K, Takayama K, Sato K. Tamura T, et al. Among authors: fukuhara t. Nat Commun. 2023 May 16;14(1):2800. doi: 10.1038/s41467-023-38435-3. Nat Commun. 2023. PMID: 37193706 Free PMC article.
Virological characteristics of the SARS-CoV-2 BA.2.86 variant.
Tamura T, Mizuma K, Nasser H, Deguchi S, Padilla-Blanco M, Oda Y, Uriu K, Tolentino JEM, Tsujino S, Suzuki R, Kojima I, Nao N, Shimizu R, Wang L, Tsuda M, Jonathan M, Kosugi Y, Guo Z, Hinay AA Jr, Putri O, Kim Y, Tanaka YL, Asakura H, Nagashima M, Sadamasu K, Yoshimura K; Genotype to Phenotype Japan (G2P-Japan) Consortium; Saito A, Ito J, Irie T, Tanaka S, Zahradnik J, Ikeda T, Takayama K, Matsuno K, Fukuhara T, Sato K. Tamura T, et al. Among authors: fukuhara t. Cell Host Microbe. 2024 Feb 14;32(2):170-180.e12. doi: 10.1016/j.chom.2024.01.001. Epub 2024 Jan 26. Cell Host Microbe. 2024. PMID: 38280382 Free article.
Virological characteristics of a SARS-CoV-2-related bat coronavirus, BANAL-20-236.
Fujita S, Plianchaisuk A, Deguchi S, Ito H, Nao N, Wang L, Nasser H, Tamura T, Kimura I, Kashima Y, Suzuki R, Suzuki S, Kida I, Tsuda M, Oda Y, Hashimoto R, Watanabe Y, Uriu K, Yamasoba D, Guo Z, Hinay AA Jr, Kosugi Y, Chen L, Pan L, Kaku Y, Chu H, Donati F, Temmam S, Eloit M, Yamamoto Y, Nagamoto T, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Suzuki Y; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ito J, Ikeda T, Tanaka S, Matsuno K, Fukuhara T, Takayama K, Sato K. Fujita S, et al. Among authors: fukuhara t. EBioMedicine. 2024 Jun;104:105181. doi: 10.1016/j.ebiom.2024.105181. Epub 2024 Jun 4. EBioMedicine. 2024. PMID: 38838469 Free PMC article.
Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.
Nomura M, Ohuchi M, Sakamoto Y, Kudo K, Yaku K, Soga T, Sugiura Y, Morita M, Hayashi K, Miyahara S, Sato T, Yamashita Y, Ito S, Kikuchi N, Sato I, Saito R, Yaegashi N, Fukuhara T, Yamada H, Shima H, Nakayama KI, Hirao A, Kawasaki K, Arai Y, Akamatsu S, Tanuma SI, Sato T, Nakagawa T, Tanuma N. Nomura M, et al. Among authors: fukuhara t. Nat Commun. 2023 Dec 13;14(1):8095. doi: 10.1038/s41467-023-43630-3. Nat Commun. 2023. PMID: 38092728 Free PMC article.
Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study.
Akahata W, Sekida T, Nogimori T, Ode H, Tamura T, Kono K, Kazami Y, Washizaki A, Masuta Y, Suzuki R, Matsuda K, Komori M, Morey AL, Ishimoto K, Nakata M, Hasunuma T, Fukuhara T, Iwatani Y, Yamamoto T, Smith JF, Sato N. Akahata W, et al. Among authors: fukuhara t. Cell Rep Med. 2023 Aug 15;4(8):101134. doi: 10.1016/j.xcrm.2023.101134. Cell Rep Med. 2023. PMID: 37586325 Free PMC article. Clinical Trial.
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Imamura T, Sonoyama T, Fukuhara T, Ichihashi G, Sanaki T, Baba K, Takeda Y, Tsuge Y, Uehara T. Mukae H, et al. Among authors: fukuhara t. Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0069722. doi: 10.1128/aac.00697-22. Epub 2022 Sep 13. Antimicrob Agents Chemother. 2022. PMID: 36098519 Free PMC article. Clinical Trial.
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Seike M, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Kawashima Y, et al. Among authors: fukuhara t. Lancet Respir Med. 2022 Jan;10(1):72-82. doi: 10.1016/S2213-2600(21)00166-1. Epub 2021 Aug 26. Lancet Respir Med. 2022. PMID: 34454653 Clinical Trial.
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Nishio M, Ohe Y, Ikeda S, Yokoyama T, Hayashi H, Fukuhara T, Sato Y, Tanaka H, Hotta K, Sugawara S, Daga H, Okamoto I, Kasahara K, Naito T, Li L, Gupta RG, Bushong J, Mizutani H. Nishio M, et al. Among authors: fukuhara t. Int J Clin Oncol. 2023 Oct;28(10):1354-1368. doi: 10.1007/s10147-023-02390-2. Epub 2023 Aug 7. Int J Clin Oncol. 2023. PMID: 37548831 Free PMC article. Clinical Trial.
828 results